Clinical Updates in Psoriatic Arthritis

November 25, 2021

Ana-Maria Orbai, MD, FACR, MHS, explains how guselkumab improved PROMIS-29 scores in patients with psoriatic arthritis.

November 04, 2021

Laure Gossec, MD, PhD discusses the association between improvements in patient-reported outcomes and disease activity in patients with psoriatic arthritis.

October 25, 2021

The risk of adverse outcomes increased the most in pregnancies with antirheumatic treatment, especially those treated with biologic disease modifying antirheumatic drugs (bDMARDs), when compared with controls.

October 20, 2021

A significant number of patients with psoriatic arthritis fail to achieve adequate disease control, resulting in health-related quality of life (HRQOL) impairments.

October 19, 2021

Dactylitis, a uniform swelling of an entire digit, occurs in up to half of patients with psoriatic arthritis and is sometimes the first manifestation of the condition.

October 18, 2021

Jeffrey Stark, MD, discusses the recent studies, BE BRIGHT, BE SURE, and BE VIVID, in which investigators analyzed the impact bimekizumab had on patients with psoriasis.

October 12, 2021

The post hoc analyses evaluated health-related quality of life and efficacy across 4 subgroups treated with either ixekizumab or adalimumab.

October 06, 2021

Test-retest reliability for Health Assessment Questionnaire–Disability Index and 36-item Short Form Health Survey physical functioning domain in patients with psoriatic arthritis was judged to be good and reasonable, respectively.

September 15, 2021

The efficacy evaluation of golimumab is crucial for patients with psoriatic arthritis, particularly for treating skin manifestations and psoriasis symptoms.

September 14, 2021

Early diagnosis and treatment of psoriatic arthritis leads to better long-term outcomes. Despite this, most patients have significant diagnostic delays.